Automated ankle pressure devices for finding peripheral arterial disease
Tests how accurately two automated devices detect peripheral arterial disease in adults.
Key facts
- Who runs it
- Hull University Teaching Hospitals NHS Trust
- Where
- Hull, United KingdomSee the site
- Trial code
- Registry title
- Automated ABPI in Peripheral Arterial Disease a Pilot Study
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 24 Jun 2026
- Expected to end
- Sept 2028
- Type of study
- Observational, 4 groups
- Treatments tested
- MESI mTablet
- BlueDop vascular Expert (BlueDopVE)
- Record updated
- 1 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults to test two automated ankle-arm blood pressure devices for peripheral arterial disease (poor blood flow to the legs). It includes people without symptoms who have heart risk factors, people with suspected disease, and people checked after leg bypass surgery.
- Age
- 18 years and over
- Sex
- All
- Disease stage
- Four groups: no symptoms but at risk, with at least 1 heart and blood vessel risk factor and no PAD diagnosis; suspected leg pain on walking (intermittent claudication) referred to the claudication clinic; suspected severe blood flow loss (CLTI, rest pain or tissue loss) referred to the vascular HOT clinic; or past leg bypass surgery and attending the local check-up programme.
- Earlier treatment
- Group 3 must have had lower limb bypass surgery. People who had a stent or graft reaching down to the ankle cannot join.
Main reasons for not taking part
- Leg surgery in the last 4 weeks or less
- Ulcers, casts or bandages that cannot be squeezed by a cuff
- Known or suspected acute deep vein thrombosis (DVT) or superficial thrombophlebitis
- Marked swelling in one or both feet, or cannot lie flat on the back
- Spasms or tremors, an arm arteriovenous fistula, or unable to give consent or cooperate
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Group 1: Asymptomatic
- Adults aged 18 and over
- At risk of PAD with ≥1 cardiovascular risk factor
- No previous diagnosis of PAD
- English speaking and able to understand test protocols; Group 2a: Suspected PAD (intermittent claudication)
- Adults aged 18 and over
- Referred and booked into the nurse-led claudication clinic due to signs/symptoms in keeping with suspected intermittent claudication
- English speaking and able to understand test protocols; Group 2b: Suspected PAD (CLTI)
- Adults aged 18 and over
- Referred and booked into the vascular HOT clinic due to signs/symptoms in keeping with suspected CLTI
- English speaking and able to understand test protocols; Group 3: Post-bypass surveillance
- Adults aged 18 and over
- History of lower limb bypass surgery, enrolled in and attending the local surveillance programme
- English speaking and able to understand test protocols
Who cannot take part
- Recent (≤4 weeks) lower-limb surgery
- Patients with known or suspected acute deep vein thrombosis (DVT) or superficial thrombophlebitis
- Arm arteriovenous fistula
- Patients who are unable to provide informed consent
- Ulcers, casts or bandages that cannot or should not be compressed
- Patients who have had a therapeutic intervention (stent or graft) which extends to the ankle
- Marked oedema in one or both feet
- Inability to tolerate a supine position
- Patients with spasms or tremors of any kind
- Inability to cooperate due to impaired cognition
Where in United Kingdom
- Hull University Teaching Hospitals NHS TrustHull, United KingdomContact: James IllingworthTaking people
About the trial
What the trial wants to find out
The aim of this pilot study is to investigate the diagnostic accuracy of two automated ABPI devices across the spectrum of PAD (asymptomatic PAD, suspected symptomatic PAD [IC; including mild moderate and severe IC based on the Rutherford classification (21) and CLTI] and post-bypass surveillance). A second aim is to assess their useability and tolerability through semi-structured interviews with patients and clinicians. This means the research will be split into two workstreams.
The 4 groups in the trial
- Group 1 Asymptomatic
Participants with one or more CVD risk factors
Treatment: MESI mTablet and BlueDop vascular Expert (BlueDopVE)
- Group 2a Suspected PAD (intermittent claudication)
Partcipants presenting with Suspected PAD (intermittent claudication)
Treatment: MESI mTablet and BlueDop vascular Expert (BlueDopVE)
- Group 2b Suspected PAD (CLTI)
Participants presenting with tissue loss or rest pain
Treatment: MESI mTablet and BlueDop vascular Expert (BlueDopVE)
- Group 3 Post-bypass surveillance
Participants presenting for post-bypass surveillance
Treatment: MESI mTablet and BlueDop vascular Expert (BlueDopVE)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Assessing the Diagnostic Accuracy of AUTOmated Ankle-Brachial Pressure Index Devices Across the Spectrum of Peripheral Arterial Disease (AUTO-PAD)- A Pilot Study
- Plain-language title
- Automated ankle pressure devices for finding peripheral arterial diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 1 October 2026